STOCK TITAN

Zenas BioPharma (ZBIO) Stock News

ZBIO NASDAQ

Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.

Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.

Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.

This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) granted stock options and restricted stock units to new hires on November 16, 2026. The awards, made under Nasdaq Listing Rule 5635(c)(4), include options to buy 225,000 common shares and 9,000 restricted stock units.

The options have a 10-year term and a $27.93 exercise price per share, equal to the common stock’s closing price on the grant date. Both awards vest over four years, subject to continued employment or other service through the applicable vesting dates. The awards are governed by the 2026 Inducement Plan and applicable award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) launched The Distance Between, an educational platform focused on experiences of people living with IgG4-related disease. The platform draws on company-sponsored surveys of 70 U.S. adults with the disease and 61 physicians, conducted online in August 2026.

Among patients, 61% reported frequently or constantly worrying about progression or what might happen between flares, compared with 48% of physicians who believed patients had that level of concern. Treatment-goal discussions were reported often or always by 90% of physicians, versus 65% of patients. Zenas aims to use educational resources and personal stories to support conversations between patients and care teams about disease burden and long-term management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (ZBIO) announced that management will present at the Jefferies London Global Healthcare Conference on November 16, 2026. The presentation is scheduled for 5:00 p.m. GMT. A live webcast and archived replay will be available under “Events and Presentations” in the Investor & Media Relations section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
none
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) reported a third-quarter 2026 net loss of $108.9 million while advancing obexelimab toward potential regulatory approval. The loss compared with $51.5 million a year earlier. Revenue was $10.0 million, versus none, from a Bristol Myers Squibb development milestone. Cash, cash equivalents and investments totaled $647.1 million at September 30.

The FDA accepted obexelimab’s application for IgG4-related disease, with a May 27, 2027 target decision date; the European Medicines Agency validated its application. Zenas expects fourth-quarter 2026 results from the Phase 2 SunStone lupus trial and initial Phase 1 ZB021 data. It expects funding to last at least through the second quarter of 2029, assuming a potential $75 million Royalty Pharma milestone and a $75 million Pharmakon debt draw associated with FDA approval. Jerald Korn became chief legal and strategy officer in October.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.89%
Tags
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) granted 74,900 restricted stock units to newly hired employees on October 15, 2026, as employment inducements.

The awards, which represent rights to shares of common stock, vest in four equal annual installments: 25% on each of October 15, 2027, 2028, 2029 and 2030. Vesting requires continued service through each applicable date. The Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4), subject to the 2026 Inducement Plan and applicable award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) presented new obexelimab findings in IgG4-related disease from the Phase 3 INDIGO trial and its extension. The data were presented at the October 8–10, 2026 international symposium in Cambridge, Massachusetts.

In the open-label extension, where participants knew their treatment, the 12-month probability of remaining flare-free was 0.93 using investigator- and committee-confirmed flares requiring rescue therapy, versus 0.87 using investigator-determined flares requiring rescue therapy; five patients awaited adjudication. At week 52, cumulative steroid toxicity was lower versus placebo, with a score difference of -11.4; p=0.021. Initial vaccine sub-study findings showed blood markers of immunity to influenza in 6 of 7 participants and COVID-19 in 4 of 4 following vaccination during a treatment-free window.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) will present seven posters at MSToronto2026, the Joint ACTRIMS-ECTRIMS Meeting, on October 21–23, 2026, in Toronto, Canada.

Orelabrutinib presentations cover how the drug is processed in the body in relapsing-remitting multiple sclerosis, designs of the Monarch and PriMroSe Phase 3 trials in progressive multiple sclerosis, and 24-week efficacy and safety results for the 80 mg dose in a Phase 2 study. Obexelimab presentations cover biomarkers and disease activity, 24-week results, and how the drug is processed and acts in the body, all from the Phase 2 MoonStone trial in relapsing multiple sclerosis.

Zenas will also host an expert-panel symposium on BTK inhibition and disability progression in multiple sclerosis on October 21, from 5:30–6:30 p.m. ET. The four paper-poster presentations are scheduled for October 22, from 4:30–6:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.60%
Tags
-
Rhea-AI Summary

Zenas BioPharma (ZBIO) will host a virtual research and development event on October 27, 2026, featuring management presentations on its pipeline. The event runs from 8:00–9:30 a.m. ET and will cover investigational obexelimab, currently being evaluated in systemic lupus erythematosus, and ongoing development of ZB021. Dr. Joseph F. Merola will discuss biology and clinical considerations. A webcast replay will be available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.20%
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (ZBIO) will present new Phase 3 INDIGO data on obexelimab in immunoglobulin G4‑related disease (IgG4‑RD) at two scientific meetings in October and November 2026.

Longer‑term flare protection and safety data from the INDIGO open‑label extension will be presented on October 10 at the IgG4ward! 6th International Symposium on IgG4‑Related Disease in Cambridge, Massachusetts. Across this symposium and ACR Convergence 2026 in Orlando, presentations will also cover glucocorticoid‑associated toxicity and influenza/SARS‑CoV‑2 vaccine responses in patients with IgG4‑RD treated with obexelimab, through both oral and poster sessions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary

Zenas BioPharma (ZBIO) granted equity awards to new employees on September 15, 2026 under Nasdaq Listing Rule 5635(c)(4).

The awards comprise non-qualified stock options for an aggregate 53,700 common shares and 98,900 restricted stock units as inducements to join the company. The options have a ten-year term with an exercise price of $31.93, equal to the Grant Date closing price. Option vesting occurs over four years, with 25% after one year of employment and the balance in 36 equal monthly installments. RSUs vest in four equal annual installments on September 15 of 2027, 2028, 2029 and 2030, subject to continued service and the terms of the 2026 Inducement Plan and award agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none

FAQ

What is the current stock price of Zenas BioPharma (ZBIO)?

Zenas BioPharma (ZBIO) last closed at $26.42.

What is the market cap of Zenas BioPharma (ZBIO)?

The market cap of Zenas BioPharma (ZBIO) is approximately $1.8B.